Terbinafine gel - MediQuest Therapeutics
Alternative Names: IVR-101; MQX-5866; MQX-5867; Organogel - MediQuest Therapeutics; Organogel of terbinafine 2% or 6%Latest Information Update: 02 Oct 2021
At a glance
- Originator MediQuest Therapeutics
- Developer Ivrea Pharmaceuticals
- Class Amines; Antifungals; Naphthalenes; Skin disorder therapies; Small molecules
- Mechanism of Action Squalene monooxygenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Onychomycosis
Most Recent Events
- 09 Feb 2016 No development reported - Phase-II for Onychomycosis in USA (Topical)
- 28 Aug 2012 Clinical development is ongoing in USA
- 28 Aug 2012 Onychomycosis therapies (topical gels) - MediQuest is available for licensing as of 28 Aug 2012. http://www.mqti.com